The IGF/IGF-I receptor signaling pathway as a potential target for cancer therapy

Drug Resistance Updates

Volumn 2, Issue 1, 1999, Pages 3-8

  Burtscher, Ingo ^a   Christofori, Gerhard ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DAUNORUBICIN; ETOPOSIDE; FULVESTRANT; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TYROSINE KINASE RECEPTOR; VINCRISTINE;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL CYCLE; CELL TRANSFORMATION; DRUG SENSITIZATION; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0033081582     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1998.0061     Document Type: Review

References (59)

1. LeRoith D. Insulin-like Growth Factors: Molecular and Cellular Aspects. 1991;CRC Press, Boca Raton.
2. Schofield P. N. The Insulin-like Growth Factors: Structure and Biological Function. 1992;Oxford University Press, Oxford.
3. Baserga R., Hongo A., Rubini M., Prisco M., and Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochem Biophys Acta. 1332:1997;F105-F126.
4. Rubin R and and Baserga R. Biology of disease: insulin-like growth factor-1 receptor. Lab. Invest. 73:1995;311-331.
5. Filson A. J., Louvi A., Efstratiadis A., Robertson E.J. Rescue of the T-associated maternal effect in mice carrying null mutations in Igf-2 and Igf2r, two reciprocally imprinted genes. Development. 118:1993;731-736.
6. Ludwig T., Eggenschwiler J., Fisher P., D'Ercole A. J., Davenport M. L., Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol. 177:1996;517-535.
7. Manfredi J. J., Prives C. The transforming activity of simian virus 40 large tumor antigen. Biochim Biophys Acta. 1198:1994;65-83.
8. Baker J., Liu J. P., Robertson E. J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 75:1993;73-82.
9. Liu J. P., Baker J., Perkins A. S., Robertson E. J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type I IGF receptor (Igf1r). Cell. 75:1993;59-72.
10. Merimee T. J., Zapf J., Froesch E. R. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med. 309:1983;527-530.
11. Godowski P. J., Leung D. W., Meacham L. R. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci U S A. 86:1989;8083-8087.
12. Ward A. Beck-Wiedemann syndrome and Wilms' tumour. Mol Hum Reprod. 3:1997;157-168.
13. Eggenschwiler J., Ludwig T., Fisher P., Leighton P. A., Tilghman S. M., Efstratiadis A. Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev. 11:1997;3128-3142.
14. Sell C., Dumenil G., Deveaud C. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 14:1994;3604-3612.
15. DeAngelis T., Ferber A., Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol. 164:1995;214-221.
16. Coppola D., Ferber A., Miura M. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol. 14:1994;4588-4595.
17. Sell C., Rubini M., Rubin R., Liu J. P., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A. 90:1993;11217-11121.
18. Morrione A., DeAngelis T., Baserga R. Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. J Virol. 69:1995;5300-5303.
19. Boyle C. C., Hickman J. A. Toxin-induced increase in survival factor receptors: modulation of the threshold for apoptosis. Cancer Res. 57:1997;2404-2409.
20. Flossmann-Kast B. B., Jehle P. M., Hoeflich A., Adler G., Lutz M. P. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res. 58:1998;3551-3554.
21. Baserga R. The price of independence. Exp Cell Res. 236:1997;1-3.
22. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 369:1994;414-418.
23. Naik P., Karrim J., Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev. 10:1996;2105-2116.
24. Evan G. I., Wyllie A. H., Gilbert C. S. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128.
25. Harrington E. A., Bennett M. R., Fanidi A., Evan G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:1994;3286-3295.
26. Fanidi A., Harrington E. A., Evan G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature. 359:1992;554-556.
27. Hueber A. O., Zornig M., Lyon D., Suda T., Evan G. I. Requirement for the CD95 receptor-ligand pathway in c-Myc- induced apoptosis. Science. 278:1997;1305-1309.
28. D'Ambrosio C., Valentinis B., Prisco M., Resis K., Rubini M., Baserga R. Protective effect of the insulin-like growth factor I receptor on apoptosis induced by okadaic acid. Cancer Res. 57:1997;3264-3271.
29. Raff M. C., Barres B. A., Burne J. F., Coles H. S., Ishizaki Y., Jacobson M. D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 262:1993;695-700.
30. Dunn S. E., Ehrlich M., Sharp N. J. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58:1998;3353-3361.
31. Warren R. S., Yuan H., Matli M. R., Ferrara N., Donner D. B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 271:1996;29483-29488.
32. Goad D. L., Rubin J., Wang H., Tashjian A. H. Jr, Patterson C. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology. 137:1996;2262-2268.
33. Kim K. W., Bae S. K., Lee O. H., Bae M. H., Lee M. J., Park B. C. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 58:1998;348-351.
34. Li S., Ferber A., Miura M., Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. J Biol Chem. 269:1994;32558-32564.
35. Surmacz E., Sell C., Swantek J. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp Cell Res. 218:1995;370-380.
36. Hongo A., D'Ambrosio C., Miura M., Morrione A., Baserga R. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene. 12:1996;1231-1238.
37. Blakesley V. A., Koval A. P., Stannard B. S., Scrimgeour A., LeRoith D. Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth. J Biol Chem. 273:1998;18411-18422.
38. O'Connor R., Kauffmann-Zeh A., Liu Y. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol. 17:1997;427-435.
39. D'Ambrosio C., Hongo A., Li S., Baserga R. The role of Grb2 in the growth and transformation of mouse embryo cells. Oncogene. 12:1996;371-378.
40. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 385:1997;544-548.
41. Hunter T. Protein kinases and phosphatases: the yin and Yang of protein phosphorylation and signaling. Cell. 80:1995;225-236.
42. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol. 10:1998;262-267.
43. Dudek H., Datta S. R., Franke T. F. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275:1997;661-665.
44. Kulik G., Klippel A., Weber M. J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 17:1997;1595-1606.
45. Carpenter C. L., Cantley L. C. Phosphoinositide kinases. Curr Opin Cell Biol. 8:1996;153-158.
46. Franke T. F., Kaplan D. R., Cantley L. C. PI3K: downstream AKTion blocks apoptosis. Cell. 88:1997;435-437.
47. Alessi D. R., Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev. 8:1998;55-62.
48. Datta S. R., Dudek H., Tao X. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
49. Parrizas M., Saltiel A. R., LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 272:1997;154-161.
50. Kulik G., Weber M. J. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol. 18:1998;6711-6718.
51. Lamm G. M., Christofori G. Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells. Cancer Res. 58:1998;801-807.
52. Nickerson T., Huynh H., Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 28:1997;690-693.
53. Guvakova M. A., Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 57:1997;2606-2610.
54. Gill Z. P., Perks C. M., Newcomb P. V., Holly J. M. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 272:1997;25602-25607.
55. Damon S. E., Maddison L., Ware J. L., Plymate S. R. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology. 139:1998;3456-3464.
56. Pietrzkowski Z., Wernicke D., Porcu P., Jameson B. A., Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 52:1992;6447-6451.
57. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B. A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1993;1102-1106.
58. Häyry P., Myllärniemi M., Aaav ik E. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9:1995;1336-1344.
59. Mohammadi M., Froum S., Hambry J. M. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17:1998;5896-5904.